- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Talquetamab-Based Triplet Elicits Deep Responses in R/R Myeloma
September 27th 2024, 6:04pm
International Myeloma Society Annual Meeting
Talquetamab plus daratumumab yields improved patient outcomes in patients with relapsed/refractory multiple myeloma.
Talquetamab Plus Teclistamab Demonstrates Durable Responses in Triple Class–Exposed R/R Myeloma
September 27th 2024, 2:56pm
International Myeloma Society Annual Meeting
Combining talquetamab with teclistamab demonstrated responses even among those with extramedullary disease in the RedirecTT-1 trial.
Radium-223 Before Docetaxel Demonstrates Better QOL in mCRPC, With No Difference in Survival
September 27th 2024, 1:15pm
Radium-223 prior to docetaxel improved quality of life and tolerability in patients with metastatic castration-resistant prostate cancer according to data from the RAPSON trial.
D-VRd Extends PFS in Newly Diagnosed Multiple Myeloma Subgroups
September 26th 2024, 4:55pm
International Myeloma Society Annual Meeting
D-VRd induction and consolidation therapy displayed a PFS benefit vs VRd in high-risk subgroups of patients with newly diagnosed multiple myeloma.
Belantamab Mafodotin Plus VRd Demonstrates Efficacy in Newly Diagnosed, Transplant-Eligible Myeloma
September 26th 2024, 2:52pm
International Myeloma Society Annual Meeting
Belantamab mafodotin-based combination appears to improve responses over time in those with transplant-eligible newly diagnosed multiple myeloma
Experts Share Intriguing Early-Phase Sarcoma Studies From the 2024 ESMO Congress
September 25th 2024, 2:05pm
Read about the early-phase sarcoma studies presented at the 2024 ESMO Congress that experts are keeping their eyes on.
Adjuvant Pembrolizumab Prolongs DFS Regardless of PD-L1 or Nodal Status in High-Risk MIBC
September 25th 2024, 12:00pm
Adjuvant pembrolizumab generated a DFS benefit vs observation in patients with high-risk muscle-invasive bladder cancer after radical surgery.
Breastfeeding During Endocrine Therapy Interruption Is Feasible, Does Not Adversely Affect Recurrence Rates in HR+ Breast Cancer
September 24th 2024, 1:00pm
Patients with HR-positive breast cancer who conceived during a break from endocrine therapy found breastfeeding feasible and safe.
NKT2152 Data Reinforce the Importance of HIF2α Inhibition in Advanced Clear Cell RCC
September 19th 2024, 5:13pm
The novel oral HIF2α inhibitor NKT2152 elicited encouraging responses in patients with previously treated advanced clear cell renal cell carcinoma.
CheckMate-9ER Post-Hoc Analysis Seeks to Identify Efficacy Biomarkers for Nivolumab/Cabozantinib in RCC
September 19th 2024, 12:00pm
Elevated fucosylation and sialylation of serum proteins were negative prognostic factors in RCC after treatment with nivolumab plus cabozantinib or sunitinib.
Elacestrant Plus Abemaciclib Demonstrates Clinical Benefit in Pretreated ER+/HER2– Metastatic Breast Cancer
September 18th 2024, 9:32pm
Elacestrant plus abemaciclib demonstrated clinical activity and manageable safety in pretreated ER+/HER2– metastatic breast cancer.
Experts Highlight Top Findings From the 2024 IASLC World Conference on Lung Cancer
September 18th 2024, 6:00pm
IASLC World Conference on Lung Cancer
Experts across the lung cancer treatment space impart their key takeaways from research shared at the 2024 IASLC World Conference on Lung Cancer.
Lenvatinib Plus Pembrolizumab Affords Deep and Durable Responses in Endometrial Cancer
September 18th 2024, 2:40pm
Lenvatinib plus pembrolizumab led to tumor responses regardless of mismatch repair–proficient status, histology, and prior adjuvant therapy.
Dato-DXd Demonstrates Efficacy, Safety in Platinum-Resistant Ovarian and Endometrial Cancers
September 18th 2024, 2:00pm
Datopotamab deruxtecan shows antitumor activity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy.
Ipilimumab Plus Nivolumab Increases 12-Month OS Rate vs SOC in nccRCC
September 17th 2024, 8:00pm
Ipilimumab given in combination with nivolumab met the primary end point of 12-month OS rate vs SOC in patients with nccRCC in the SUNNIFORECAST trial.
Benmelstobart Plus Anlotinib Demonstrates Efficacy in Frontline Advanced RCC
September 17th 2024, 6:00pm
Benmelstobart plus anlotinib improved PFS, OS, and ORR vs sunitinib in first-line advanced renal cell carcinoma.
Neoadjuvant Chemotherapy Could Enhance Organ Preservation in Nasal and Paranasal Sinus Squamous Cell Carcinoma
September 17th 2024, 12:00pm
Neoadjuvant chemotherapy improved organ preservation in nasal and paranasal sinus squamous cell carcinoma.
Dr Andre on the Efficacy of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC Subgroups
September 16th 2024, 11:10pm
Thierry Andre, MD, discusses subgroup and safety analyses of the phase 3 CheckMate 8HW trial of frontline nivolumab plus ipilimumab in MSI-H/dMMR mCRC.
Fianlimab/Cemiplimab Demonstrates Persistent Activity in Advanced Melanoma, Independent of LAG-3 and PD-L1 Status
September 16th 2024, 9:20pm
Fianlimab plus cemiplimab demonstrated persistent and significant clinical activity in patients with advanced melanoma.
Several IO Combos Miss Efficacy Target in NSCLC, But Clinical Benefit Seen With 2 Combos
September 16th 2024, 8:49pm
Durvalumab plus monalizumab and durvalumab plus ceralasertib showed promising long-term benefits in advanced NSCLC.